Sign inCreate account

Report workspace

Add to folder
NCT07113496NOT_YET_RECRUITINGanonymous

An Exploratory Clinical Study on the Safety and Efficacy of Allogeneic CAR-T Cell (RN1201) for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Sponsor

Source record

The First Affiliated Hospital with Nanjing Medical University

Phase

Source record

Phase 1

Modality

AI-normalized

cell therapy

Target

AI-normalized

CD19 and BCMA (B-cell maturation antigen)

Indication / condition

AI-normalized

Relapsed or Refractory B-cell Hematologic Malignancies

Intervention

Source record

Allogeneic CAR-T

Source & freshness

Source record

NCT ID

NCT07113496

Original source

ClinicalTrials.gov

Source last updated

Aug 13, 2025

Ingested at

Jun 13, 2026

Internal sync

Jun 13, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT07113496

Title

An Exploratory Clinical Study on the Safety and Efficacy of Allogeneic CAR-T Cell (RN1201) for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Status

NOT_YET_RECRUITING

Phase

Phase 1

Condition raw

Relapsed or Refractory B-cell Hematologic Malignancies, B-cell Acute Lymphoblastic Leukemia (B-ALL), Multiple Myeloma (MM), Plasmablastic Lymphoma, Relapsed or Refractory CD19+/BCMA+ Hematologic Malignancies, Mature B-Cell Lymphoma

Condition normalized

Relapsed or Refractory B-cell Hematologic Malignancies, B-cell Acute Lymphoblastic Leukemia (B-ALL), Multiple Myeloma (MM), Plasmablastic Lymphoma, Relapsed or Refractory CD19+/BCMA+ Hematologic Malignancies, Mature B-Cell Lymphoma

Modality raw

cell therapy

Modality normalized

cell therapy

Target raw

CD19 and BCMA (B-cell maturation antigen)

Target normalized

CD19 and BCMA (B-cell maturation antigen)

Interventions

Allogeneic CAR-T

Public preview

Source record

The exploratory trial for RN1201, an allogeneic CAR-T cell therapy targeting CD19 and BCMA, addresses a significant unmet need in the treatment of relapsed or refractory hematologic malignancies, particularly multiple myeloma and B-cell acute lymphoblastic leukemia. The trial's focus on patients with minimal residual disease (MRD) may enhance its appeal in a competitive landscape dominated by autologous CAR-T therapies. Given the increasing prevalence of hematologic cancers and the growing acceptance of CAR-T therapies, successful outcomes could position RN1201 favorably in a lucrative market. However, the trial is not yet recruiting, which may delay potential market entry and necessitate close monitoring of competitor advancements in similar therapeutic areas.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Exploratory Clinical Study on the Safety and Efficacy of Allogeneic CAR-T Cell (RN1201) for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT07113496

Status

NOT_YET_RECRUITING

Phase

Phase 1

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Executive brief

Investment-Ready Snapshot

The exploratory trial for RN1201, an allogeneic CAR-T cell therapy targeting CD19 and BCMA, addresses a significant unmet need in the treatment of relapsed or refractory hematologic malignancies, particularly multiple myeloma and B-cell acute lymphoblastic leukemia. The trial's focus on patients with minimal residual disease (MRD) may enhance its appeal in a competitive landscape dominated by autologous CAR-T therapies. Given the increasing prevalence of hematologic cancers and the growing acceptance of CAR-T therapies, successful outcomes could position RN1201 favorably in a lucrative market. However, the trial is not yet recruiting, which may delay potential market entry and necessitate close monitoring of competitor advancements in similar therapeutic areas.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedAug 13, 2025
Internal syncJun 13, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07113496

Indication

Relapsed or Refractory B-cell Hematologic Malignancies

Modality

cell therapy

Target

CD19 and BCMA (B-cell maturation antigen)

Intervention

Allogeneic CAR-T

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.